SCHEMBL19900340

SCHEMBL19900340

CCCCCCCCCCCCCCc1nc(N2CCC2)nc(OC2CCC2)c1O

nearest known ligand 0.46

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18005522 0.98 MEN1 (0.32) CHRM1
SCHEMBL18005212 0.97 SMN1; SMN2 (0.32) —
SCHEMBL19890899 0.90 — —
SCHEMBL18005617 0.86 CHRM1 (0.30) CHRM1
SCHEMBL19900683 0.86 CHRM1 (0.30) CHRM1
SCHEMBL18005415 0.84 KCNQ3 (0.38) —
SCHEMBL18005537 0.84 MEN1 (0.32) CHRM1
SCHEMBL22509220 0.83 SMN1; SMN2 (0.35) CHRM1
SCHEMBL18005359 0.83 SMN1; SMN2 (0.35) CHRM1
SCHEMBL19900229 0.82 NAAA (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595250-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2026-04-07 — — US disclosed
US-20220324841-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2022-10-13 — — US disclosed
US-11390605-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2022-07-19 — — US disclosed
US-20210276979-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-09-09 — — US disclosed
US-20210276979-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2021-09-09 — — US disclosed
WO-2018039077-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-01 — — WO disclosed
WO-2018039077-A1 THERAPEUTIC COMPOUNDS ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2018-03-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595250-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses GSR, UQCRC1, TXNRD2 CHRM1 1222/4885
US-20220324841-A1 THERAPEUTIC COMPOUNDS CFTR, F12, FURIN CHRM1 823/4885
US-20210276979-A1 THERAPEUTIC COMPOUNDS CFTR, F12, FURIN CHRM1 823/4885
US-11390605-B2 Substituted pyrimidine compounds as multifunctional radical quenchers and their uses DPYD, TYMP, NUDT1 CHRM1 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback